CliffBio
small molecule

BRISDELLE

PAROXETINE MESYLATE

Loss of exclusivityApril 2029latest FDA-listed patent expiry
CompanyLEGACY PHARMA INC SEZC

Drug detail

Brand nameBRISDELLE
Active ingredientPAROXETINE MESYLATE
StrengthEQ 7.5MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2013
Marketing statusRX

Listed patents

PatentExpiresType
8658663April 2029substance, product
8946251August 2026substance, product
9393237August 2026use U-904

More from LEGACY PHARMA INC SEZC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BRISDELLE patent cliff — loss of exclusivity April 2029 | CliffBio